GSK plc ADR Stock
Price
Target price
€40.80
€40.80
-0.960%
-0.4
-0.960%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
GSK plc ADR shows a slight decrease today, losing -€0.400 (-0.960%) compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of GSK plc ADR in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -0.960% | -5.116% | -0.971% | 25.153% | -2.392% | 23.636% | 4.615% |
| Astrazeneca ADR | 0.650% | -6.627% | -1.274% | 21.094% | -1.899% | 21.473% | 79.398% |
| Bayer AG ADR | 4.000% | -0.990% | 16.279% | 100.000% | 13.636% | -28.058% | -25.373% |
| Novo Nordisk A/S ADR | 4.530% | 0.197% | 23.601% | -34.704% | 15.323% | -60.923% | -15.333% |
Comments
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK PLC Sponsored ADR (NYSE: GSK) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
Why Rapt Therapeutics Stock Soared Today
Shares of Rapt Therapeutics (NASDAQ: RAPT) surged on Tuesday after the immunology specialist struck a deal to be acquired by British pharmaceutical leader GSK (NYSE: GSK) for $2.2 billion.
By the
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit
ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 / OMP, a leader in supply chain planning solutions, is spotlighting at the Gartner Supply Chain Planning Summit 2025 in London how GSK is
